Abbott Laboratories ABT NYSE

Abbott Laboratories (ABT) generated $3.32B in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $689M, free cash flow was $2.63B.

Free cash flow margin was 22.9% of revenue. Cash conversion ratio was 1.87x, indicating earnings are backed by cash.

The company returned $1.03B in dividends and $302M in share buybacks to shareholders during the quarter.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (86/100, Pass) — $2.63B (22.9% margin) supports a durable competitive advantage
• INCOME (55/100) — Cash conversion ratio was 1.87x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 80/100 with 5/7 criteria passed.